Our Transactions
Leadership across the largest and most complex situations
Financial Advisor
on its pending $22.5 billion
acquisition of
2024
Lead Financial Advisor
on its pending €8.0 billion
acquisition of
from Vodafone Group
2024
Exclusive Financial Advisor
on its pending ~$2.3 billion
acquisition of
2024
Independent Financial Advisor
on its pending acquisition of three fill-finish sites for an upfront payment of $11 billion from Novo Holdings following its $16.5 billion acquisition of Catalent
2024
Exclusive Financial Advisor
on its pending ~$35 billion
acquisition of
2024
Exclusive Financial Advisor
on its pending ~$12.6 billion
sale to
2024
Lead Financial Advisor
on its pending $11.5 billion
all-stock merger with
2024
Lead Financial Advisor
on its pending ~$13.4 billion
sale to
2023
Financial Advisor
on its pending ~$14.9 billion
sale to
2023
Financial Advisor
on its pending $60 billion
all-stock acquisition of
2023
Financial Advisor
on its up to $5.8 billion
acquisition of
2023
Lead Left Bookrunner
$300 million
Follow-on Offering
2023
Exclusive Financial Advisor
on its chapter 11 restructuring of ~$1.9 billion of debt and $125 million DIP ABL financing
2023
Active Bookrunner
$1.1 billion IPO & $1.6 billion
Follow-on Offering
2023
Exclusive Financial Advisor
on its pre-packaged chapter 11 restructuring of ~$3.6 billion of debt and preferred equity
2023
Lead Financial Advisor
on its ~$36 billion
spinoff of
2021
Anouncement Date1
Status
Transaction
Value (M)
July 23, 2024
Closed
Advised an Ad Hoc Group of lenders on Belk’s out-of-court recapitalization
~$1,950
July 22, 2024
Pending
Advising Goodyear Tire on the sale of its OTR Tire Business to The Yokohama Rubber Company
$905
July 22, 2024
Closed
Advised Krispy Kreme on the sale of a majority of its stake in Insomnia Cookies to Verlinvest and Mistral Equity Partners
~$175
July 22, 2024
Pending
Advising Archrock on its acquisition of Total Operations and Production Services and concurrent equity offering
$983
July 19, 2024
Pending
Advising Augmedix on its sale to Commure
~$139
July 9, 2024
Pending
Advising TAIT and its sponsor, Providence Equity Partners, on the sale of a majority stake to Goldman Sachs Alternatives’ Private Equity business
N/A
July 8, 2024
Pending
Advising Morphic Therapeutic on its sale to Eli Lilly
~$3,200
July 3, 2024
Pending
Advising OMERS Infrastructure on its sale of LifeLabs to Quest Diagnostics
C$1,350
July 2, 2024
Pending
Advising Isio Group Limited and its sponsor, Exponent Private Equity, on the sale of a majority stake to Aquiline Capital Partners
N/A
June 28, 2024
Closed
Advised an Ad Hoc Group of creditors on Cano Health’s Chapter 11 Restructuring
~$1,200
1Announcement date for M&A transactions represents the date publicly announced; announcement date for restructurings represents the date publicly announced or filed; announcement date for capital markets transactions represents the pricing date.